Quantum BioPharma Featured in CTV News Investigation on Stock Manipulation Allegations

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured in CTV News' W5 program, which aired Part Three of its investigative series examining the company's allegations of stock spoofing tied to its USD $700 million lawsuit against CIBC and RBC. The episodes detail rising market-manipulation cases in Canada and highlight Quantum's call for accountability, with CEO Zeeshan Saeed reaffirming the company's commitment to defending shareholders and advancing MS research. Co-Executive Chair Anthony Durkacz is offering up to USD $7 million for information leading to a final judgment or settlement in related litigation.

The investigation comes at a critical time for market integrity in Canada, as Quantum BioPharma's case represents one of several high-profile allegations of stock manipulation currently under scrutiny. The company's lawsuit against two of Canada's largest financial institutions underscores the significant financial stakes involved and raises questions about regulatory oversight in Canadian capital markets. For investors, the case highlights the potential vulnerabilities in trading systems and the importance of transparency in market operations.

Quantum BioPharma's focus on neurodegenerative and metabolic disorders adds another dimension to the story, as the company's research and development efforts could be impacted by market volatility and investor confidence. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is developing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, making this research particularly significant for patients and the medical community.

The company's business structure includes strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. Additionally, Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025, and receives royalty payments from sales of unbuzzd(TM) products. The agreement includes royalty payments of 7% of sales until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. The company maintains 100% of the rights to develop similar products for pharmaceutical and medical uses.

The CTV News investigation brings attention to the broader implications of market manipulation allegations for biopharmaceutical companies that rely on capital markets to fund research and development. For companies like Quantum BioPharma, market integrity is essential for maintaining investor confidence and securing the funding necessary to advance medical research. The case also raises questions about the effectiveness of current regulatory frameworks in detecting and preventing sophisticated market manipulation schemes.

Investors seeking additional information about Quantum BioPharma can access the latest news and updates relating to QNTM in the company's newsroom. The investigation's timing coincides with increased regulatory scrutiny of market practices in Canada, making Quantum BioPharma's case a potential bellwether for how similar allegations might be addressed in the future. The company's commitment to pursuing legal action despite the complexity and cost of such litigation demonstrates the significant impact that alleged market manipulation can have on publicly traded companies and their shareholders.